Genprex (GNPX) Stock Price, News & Analysis

Company Overview

Genprex, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s lead product candidate is ofranergene obadenovec, also known as REQORSA Therapeutics, an investigational nonviral gene therapy designed to deliver the TUSC2 tumor-suppressor gene to cancer cells.

Genprex has primarily studied REQORSA in combination with other treatments for non-small cell lung cancer, including immune checkpoint inhibitors and targeted therapies. The company has also pursued potential applications in other solid tumors and has conducted research involving gene-therapy approaches for diabetes. These programs remain investigational and are subject to clinical and regulatory development.

Genprex was founded in 2009 and is headquartered in Austin, Texas. Its development strategy centers on using proprietary delivery systems to introduce therapeutic genes into diseased cells. The company’s programs are intended to address significant unmet medical needs, but product candidates have not been approved for commercial use.

Key Stats

• Today's Range: $2.64 to $2.93
• 50-Day Range: $2.56 to $4.87
• 52-Week Range: $2.53 to $1,210.00
• Volume: 198,547 shs
• Average Volume: 263,318 shs
• Market Capitalization: $2.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Genprex Stock Analysis - MarketRank™

Genprex scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Genprex has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Genprex has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Genprex is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genprex is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Genprex has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.87% of the float of Genprex has been sold short.

Short Interest Ratio / Days to Cover

Genprex has a short interest ratio ("days to cover") of 0.27, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genprex has recently increased by 17.31%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genprex does not currently pay a dividend.

Dividend Growth

Genprex does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Genprex has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Genprex this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Genprex to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genprex insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.25% of the stock of Genprex is held by insiders.

Percentage Held by Institutions

14.05% of the stock of Genprex is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/11/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GNPX
• CIK: 1595248
• Web: www.genprex.com
• Phone: (877) 774-4679
• Fax: N/A
• Employees: 13
• Year Founded: 2009

Profitability

• EPS (Trailing Twelve Months): ($133.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.23 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -163.12%
• Return on Assets: -128.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.76
• Quick Ratio: 6.76

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $53.16 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 820,000
• Free Float: 818,000
• Market Cap: $2.23 million
• Optionable: No Data
• Beta: -0.99